Literature DB >> 16314625

Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers.

Joan L Kramer1, Isela A Velazquez, Bingshu E Chen, Philip S Rosenberg, Jeffery P Struewing, Mark H Greene.   

Abstract

PURPOSE: Breast cancer penetrance estimates in BRCA1 mutation carriers have varied from 40% to 85%; this heterogeneity has been attributed to variations in risk among different study populations. No study has taken oophorectomy status into account in estimating penetrance. Because prophylactic oophorectomy reduces breast cancer risk by approximately 50%, we hypothesized that population differences in oophorectomy prevalence might significantly influence breast cancer penetrance estimates.
METHODS: Females from multiple-case breast/ovarian cancer families that segregate deleterious BRCA1 mutations were observed prospectively for breast cancer incidence and oophorectomy.
RESULTS: Within this cohort, 33 cases of breast cancer developed in 98 women with deleterious BRCA1 mutations during follow-up, yielding an estimated cumulative lifetime breast cancer risk of 80%. This estimate increased to 94% when the study participants were censored at the time of oophorectomy. Six of the 33 mutation-positive women who underwent oophorectomy during follow-up developed breast cancer, compared with 27 of 65 mutation carriers with intact ovaries (hazard ratio = 0.38; 95% CI, 0.15 to 0.97). Estimates of absolute breast cancer risk demonstrated that the protective effect of oophorectomy was strongest among women who were premenopausal at the time of surgery. When surgical status was ignored, the strong protective effect of oophorectomy, coupled with the high prevalence of the procedure in these families, led to a significantly lower estimate of the breast cancer penetrance in BRCA1 mutation carriers.
CONCLUSION: Differing rates of oophorectomy likely represent an underappreciated basis for a portion of the heterogeneity in estimated breast cancer penetrance described in BRCA mutation carriers, particularly mutation carriers from extensively affected, multiple-case families.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16314625     DOI: 10.1200/JCO.2005.02.9199

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  43 in total

Review 1.  The role of BRCA mutation testing in determining breast cancer therapy.

Authors:  Alison H Trainer; Craig R Lewis; Kathy Tucker; Bettina Meiser; Michael Friedlander; Robyn L Ward
Journal:  Nat Rev Clin Oncol       Date:  2010-11-09       Impact factor: 66.675

Review 2.  Evolution of the colored eco-genetic relationship map (CEGRM) for assessing social functioning in women in hereditary breast-ovarian (HBOC) families.

Authors:  June A Peters; Lindsey Hoskins; Sheila Prindiville; Regina Kenen; Mark H Greene
Journal:  J Genet Couns       Date:  2006-11-17       Impact factor: 2.537

3.  RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies.

Authors:  Antonis C Antoniou; Olga M Sinilnikova; Jacques Simard; Mélanie Léoné; Martine Dumont; Susan L Neuhausen; Jeffery P Struewing; Dominique Stoppa-Lyonnet; Laure Barjhoux; David J Hughes; Isabelle Coupier; Muriel Belotti; Christine Lasset; Valérie Bonadona; Yves-Jean Bignon; Timothy R Rebbeck; Theresa Wagner; Henry T Lynch; Susan M Domchek; Katherine L Nathanson; Judy E Garber; Jeffrey Weitzel; Steven A Narod; Gail Tomlinson; Olufunmilayo I Olopade; Andrew Godwin; Claudine Isaacs; Anna Jakubowska; Jan Lubinski; Jacek Gronwald; Bohdan Górski; Tomasz Byrski; Tomasz Huzarski; Susan Peock; Margaret Cook; Caroline Baynes; Alexandra Murray; Mark Rogers; Peter A Daly; Huw Dorkins; Rita K Schmutzler; Beatrix Versmold; Christoph Engel; Alfons Meindl; Norbert Arnold; Dieter Niederacher; Helmut Deissler; Amanda B Spurdle; Xiaoqing Chen; Nicola Waddell; Nicole Cloonan; Tomas Kirchhoff; Kenneth Offit; Eitan Friedman; Bella Kaufmann; Yael Laitman; Gilli Galore; Gad Rennert; Flavio Lejbkowicz; Leon Raskin; Irene L Andrulis; Eduard Ilyushik; Hilmi Ozcelik; Peter Devilee; Maaike P G Vreeswijk; Mark H Greene; Sheila A Prindiville; Ana Osorio; Javier Benitez; Michal Zikan; Csilla I Szabo; Outi Kilpivaara; Heli Nevanlinna; Ute Hamann; Francine Durocher; Adalgeir Arason; Fergus J Couch; Douglas F Easton; Georgia Chenevix-Trench
Journal:  Am J Hum Genet       Date:  2007-10-16       Impact factor: 11.025

4.  Competing risks analysis of correlated failure time data.

Authors:  Bingshu E Chen; Joan L Kramer; Mark H Greene; Philip S Rosenberg
Journal:  Biometrics       Date:  2007-08-03       Impact factor: 2.571

5.  What have we learned from risk-reducing salpingo-oophorectomy?

Authors:  Mark H Greene; Phuong L Mai
Journal:  J Natl Cancer Inst       Date:  2009-01-13       Impact factor: 13.506

Review 6.  Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers.

Authors:  Janet R Vos; Li Hsu; Richard M Brohet; Marian J E Mourits; Jakob de Vries; Kathleen E Malone; Jan C Oosterwijk; Geertruida H de Bock
Journal:  J Clin Oncol       Date:  2015-07-06       Impact factor: 44.544

Review 7.  The clinical management of BRCA1 and BRCA2 mutation carriers.

Authors:  Anthony P Gulati; Susan M Domchek
Journal:  Curr Oncol Rep       Date:  2008-01       Impact factor: 5.075

Review 8.  Management of hereditary breast and ovarian cancer.

Authors:  Hideko Yamauchi; Junko Takei
Journal:  Int J Clin Oncol       Date:  2017-11-28       Impact factor: 3.402

9.  Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence.

Authors:  P Shah; M Rosen; J Stopfer; J Siegfried; R Kaltman; B Mason; K Armstrong; K L Nathanson; M Schnall; S M Domchek
Journal:  Breast Cancer Res Treat       Date:  2009-07-17       Impact factor: 4.872

10.  Characteristics of health information gatherers, disseminators, and blockers within families at risk of hereditary cancer: implications for family health communication interventions.

Authors:  Laura M Koehly; June A Peters; Regina Kenen; Lindsey M Hoskins; Anne L Ersig; Natalia R Kuhn; Jennifer T Loud; Mark H Greene
Journal:  Am J Public Health       Date:  2009-10-15       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.